Replies to post #1067 on Bristol Myers Squibb (BMY)

[DewDiligence]

Addendum—BMY has projected $4B+ peak sales of Opdualag by 2029.

FDA label:
https://t.co/R7v5xodScz

[DewDiligence]

CHMP approves Opdulag for first-line melanoma:

https://finance.yahoo.com/news/bristol-myers-squibb-receives-positive-105900006.html

Opdulag, an FDC of Opdivo and Relatlimb (anti-LAG-3), received FDA approval in this indication in Mar 2022 (#msg-168259775).

[DewDiligence]

BMY will not launch Opdualag in Germany due to pricing constraints on FDC (combination) drugs:

https://endpts.com/bristol-myers-axes-german-launch-of-new-cancer-drug-citing-pricing-hurdles/

[DewDiligence]

IMMP +65% on interim (single-arm) phase-2 data for LAG-3 drug with Keytruda in NSCLC:

https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html

IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.

BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).

Please see #msg-168259768 for related info.